EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia

Mary R Christopher iD, Mariam T Nawas, John L Reagan

Bone Marrow Transplantation · 2025-02 · 60 (2) · 135-143

DOI: 10.1038/s41409-024-02465-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bone Marrow Transplantation, online erschienen am 13.11.2024. Verfasst von Mary R Christopher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Nuclear Proteins, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and is mainly classified as favorable or intermediate-risk according to the European Leukemia Net stratification. Some patients, however, either have a poor response to initial intensive chemotherapy or ultimately relapse. NPM1 mutations are common, generally stable at early relapse and AML specific, features which make them ideal targets for measurable residual disease (MRD) monitoring. MRD monitoring via molecular analysis during the course of treatment can inform the role of allogeneic stem cell transplantation (HCT) in first remission in patients with NPM1 mutated AML with high-risk co-occurring mutations, particularly FLT3-ITD, and in favorable risk patients who do not achieve defined molecular milestones. In this review, we evaluate the prognostic role of MRD monitoring in NPM1 mutated AML and its use as a predictive biomarker to refine risk stratification and inform decision making regarding treatment. We explore the impact of pre-HCT MRD positivity on post-HCT outcomes in this AML subset, and how HCT-related factors such as conditioning intensity may influence this risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteNeoplasm, ResidualNuclear ProteinsMutationHematopoietic Stem Cell TransplantationHumansNucleophosminPrognosis

Substanzen

NucleophosminNPM1 protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA. nawasm@uchicagomedicine.org.
  • Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.

ORCID-Profile: Mary R Christopher

Zitieren

APA

Christopher, M. R., Nawas, M. T., & Reagan, J. L. (2025). Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplantation, 60(2), 135-143. https://doi.org/10.1038/s41409-024-02465-2

Vancouver

Christopher MR, Nawas MT, Reagan JL. Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplantation. 2025;60(2):135-143. doi:10.1038/s41409-024-02465-2

BibTeX
@article{Christopher2025,
  author = {Christopher, Mary R and Nawas, Mariam T and Reagan, John L},
  title = {Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia},
  journal = {Bone Marrow Transplantation},
  year = {2025},
  volume = {60},
  number = {2},
  pages = {135--143},
  doi = {10.1038/s41409-024-02465-2}
}
Kostenlos starten →